作者：Albini TA,Rachitskaya A,Mandelcorn ED

　　出处：Current opinion in ophthalmology.2010-11;21(6):463-7.

　　文献类型：综述 PUBMED链接：PMID: 20842032

　　Abstract：PURPOSE OF REVIEW:To review new clinically relevant data regarding the cause and treatment... PURPOSE OF REVIEW:To review new clinically relevant data regarding the cause and treatment of scleritis that has been identified over the past 36 months.

　　RECENT FINDINGS:A recently described T-helper cell population, known as Th-17, has been implicated in scleritis. Large-scale, retrospective reviews of standard corticosteroid-sparing systemic therapies, published in the last few years, have demonstrated only moderate efficacy for any particular immunomodulatory agent, whereas new data have confirmed excellent efficacy and tolerability to subconjunctival corticosteroids.

　　SUMMARY:Improved understanding of the immunopathophysiology of scleritis offers hope for future molecule-specific drug design. Data continue to support the use of local steroids as a reasonable therapeutic option for nonnecrotizing, noninfectious anterior scleritis.

　　中文摘要：

　　目的：复习最近36月内相关的临床资料，综述巩膜炎的病因和治疗。

　　最新发现：最近发现T辅助细胞亚群(Th-17)与巩膜炎相关。近几年，大量回顾性研究表明，如果不用标准的全身激素疗法而单纯使用一种免疫调节剂治疗，任何免疫制剂仅有中等的疗效。但是，最新资料证实球结膜下注射类固醇激素具有极好的疗效和耐受性。

　　结论：了解巩膜炎的免疫病理生理学为未来开发特效的分子药物提供帮助。资料还显示皮质类固醇激素局部应用是治疗非坏死性、非感染性前部巩膜炎恰当的方法。

　　主题词：Glucocorticoids; Humans; Immunosuppressive Agents; Scleritis;